Figure 2: Characterization of liver-specific functions in patient-specific iPSC-derived HLCs. | Scientific Reports

Figure 2: Characterization of liver-specific functions in patient-specific iPSC-derived HLCs.

From: Patient-specific hepatocyte-like cells derived from induced pluripotent stem cells model pazopanib-mediated hepatotoxicity

Figure 2

(a) Gene expression of hepatic markers. Box plots with mean values shown in red. n = at least 3 independent differentiation experiments. Expression is benchmarked to that in primary human hepatocytes (PHP) which is indicated by grey line. (b) Urea production. (c) Conversion of phenacetin by CYP1A2 enzymatic activity. (d) Conversion of midazolam by CYP3A4 enzymatic activity. Data in (b–d) are average ± s.e.m of at least 3 independent differentiation experiments initiated at distinct timepoints. *p < 0.05 compared to PHP control (Bonferroni t-test).

Back to article page